Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan; Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan; Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan; Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan; Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan; The Research Foundation for Microbial Diseases of Osaka University (BIKEN), 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan; Global Center for Medical Engineering and Informatics, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Biochem Biophys Res Commun. 2021 May 21;554:166-172. doi: 10.1016/j.bbrc.2021.03.099. Epub 2021 Mar 30.
Although influenza vaccines are effective for reducing viral transmission and the severity of clinical symptoms, influenza viruses still induce considerable morbidity and mortality worldwide. Seasonal influenza viruses infect the upper respiratory tract initially but then often induce severe pulmonary complications in the lower respiratory tract. Therefore, influenza vaccines that prevent viral infection at both the upper and lower respiratory tracts are highly anticipated. Here, we examined whether using different vaccination routes for priming and boosting achieved protection in both regions of the respiratory tract. To this end, we used inactivated whole-virion influenza vaccines to immunize mice either subcutaneously or intranasally for both priming and boosting. Regardless of the route used for boosting, the levels of virus-specific IgG in plasma were higher in mice primed subcutaneously than those in control mice, which received PBS only. In addition, intranasal priming followed by subcutaneous boosting induced higher levels of virus-specific IgG in plasma than those in control mice. The levels of virus-specific nasal IgA were higher in mice that were primed intranasally than in control mice or in mice primed subcutaneously. Furthermore, intranasal priming but not subcutaneous priming provided protection against viral challenge in the upper respiratory tract. In addition, when coupled with subcutaneous boosting, both subcutaneous and intranasal priming protected against viral challenge in the lower respiratory tract. These results indicate that intranasal priming followed by subcutaneous boosting induces both virus-specific IgG in plasma and IgA in nasal washes and protects against virus challenge in both the upper and lower respiratory tracts. Our results will help to develop novel vaccines against influenza viruses and other respiratory viruses.
尽管流感疫苗可有效降低病毒传播和临床症状的严重程度,但流感病毒仍在全球范围内导致相当高的发病率和死亡率。季节性流感病毒最初感染上呼吸道,但随后常在上、下呼吸道引发严重的肺部并发症。因此,人们非常期待能预防上、下呼吸道病毒感染的流感疫苗。在这里,我们研究了通过不同的接种途径进行初免和加强免疫是否能在呼吸道的两个部位提供保护。为此,我们使用了灭活的全病毒流感疫苗对小鼠进行皮下或鼻内接种进行初免和加强免疫。无论加强免疫的途径如何,皮下初免的小鼠血浆中病毒特异性 IgG 的水平均高于仅接受 PBS 的对照组小鼠。此外,鼻内初免后皮下加强免疫诱导的血浆中病毒特异性 IgG 水平高于对照组小鼠。鼻内初免的小鼠鼻洗液中病毒特异性 IgA 的水平高于对照组小鼠或皮下初免的小鼠。此外,鼻内初免而不是皮下初免可提供对上呼吸道病毒挑战的保护。此外,当与皮下加强免疫结合时,皮下和鼻内初免均可提供对下呼吸道病毒挑战的保护。这些结果表明,鼻内初免后皮下加强免疫可诱导血浆中的病毒特异性 IgG 和鼻洗液中的 IgA,并对上、下呼吸道的病毒挑战提供保护。我们的研究结果将有助于开发针对流感病毒和其他呼吸道病毒的新型疫苗。